full timeline
Daraxonrasib pancreatic cancer trials
The targeted therapy daraxonrasib, combined with standard chemotherapy, eliminated detectable tumors in 8 percent of patients with metastatic pancreatic cancer in a new clinical trial.
Follow Daraxonrasib pancreatic cancer trials in the Factlen app and get an alert when there is news. Get the app
Share this story
Latest report
Daraxonrasib Pill Eradicates Tumors in Early Pancreatic Cancer Trial
The targeted therapy daraxonrasib, combined with standard chemotherapy, eliminated detectable tumors in 8 percent of patients with metastatic pancreatic cancer in a new clinical trial. The results offer a potential first-line alternative for a disease that has historically resisted treatment.
- Daraxonrasib combined with chemotherapy shrank tumors in 60.7 percent of patients with previously untreated metastatic pancreatic cancer.
- In 8.2 percent of treated patients, the tumors vanished entirely, achieving a complete response.
- The combination therapy extended median progression-free survival to 12.8 months, significantly outpacing historical chemotherapy outcomes.
- The European Commission recently approved daraxonrasib as a standalone second-line treatment, expanding its global regulatory footprint.
At the EORTC-NCI-AACR Symposium in Barcelona on November 19, 2026, researchers presented updated Phase 1/2 trial data for the targeted therapy daraxonrasib. When combined with standard chemotherapy, the daily pill shrank tumors in 60.7 percent of patients with previously untreated metastatic pancreatic adenocarcinoma.[1][5][6]
In 8.2 percent of the 61 patients treated in the cohort, the tumors vanished entirely. This complete response rate represents a rare outcome in a disease that has historically resisted both targeted therapies and immunotherapies. The median progression-free survival reached 12.8 months.[1][6]
"By combining daraxonrasib with chemotherapy, we are seeing remarkably deep tumour responses in a substantial proportion of patients," said Dr. W. Park, the principal investigator. He noted that the regimen provided durable disease control that outpaces the historical expectations for conventional chemotherapy.[5]
Pancreatic cancer remains one of the most lethal malignancies, largely because it is typically diagnosed after it has spread. For patients with metastatic disease, the five-year relative survival rate hovers around 3 percent globally. Most patients treated with standard chemotherapy survive for eight to eleven months.[5][6]
The new data suggests a potential shift in that prognosis. After a median follow-up of 18.3 months, the 12-month overall survival rate for the combination therapy stood at 76.6 percent. The overall disease control rate—meaning tumors either shrank or stopped growing—reached 90.2 percent.[6]
Targeting the RAS Mutation
The mechanism behind daraxonrasib represents a breakthrough in molecular biology. More than 90 percent of pancreatic ductal adenocarcinomas are driven by mutations in the RAS gene family. These genes act as molecular switches that regulate cell growth and division.[5][7]
In pancreatic cancer, the mutated RAS switch becomes permanently stuck in the "on" position, continuously sending signals that drive cancer cells to multiply. For decades, researchers considered the resulting KRAS protein "undruggable" because its smooth surface lacked obvious pockets where a drug could bind.[7]
Daraxonrasib overcomes this structural hurdle by acting as a molecular glue. The drug binds the active RAS protein to cyclophilin A, a protein that ordinarily does not interact with RAS. This tethering inactivates the oncogenic driver and suppresses the downstream signaling pathways.[7]
Unlike earlier RAS inhibitors that only target a single specific mutation, daraxonrasib is a multi-selective inhibitor. It can turn off the active protein regardless of which specific RAS variant has mutated, making it applicable to a much broader patient population.[7]
In the Phase 1/2 RMC-GI-102 trial, patients received 200 milligrams of daraxonrasib orally each day. This targeted approach was paired with intravenous gemcitabine and nab-paclitaxel, administered on days 1 and 15 of a 28-day treatment cycle.[5][6]
Expanding Regulatory Clearances
The Barcelona presentation follows a major regulatory milestone for the drug as a standalone second-line treatment. On November 16, 2026, the European Commission approved daraxonrasib monotherapy for adults with metastatic pancreatic cancer who have received at least one prior systemic therapy.[3]
The European clearance applies across all European Union member states, as well as Iceland, Norway, and Liechtenstein. The decision followed an expedited review under the European Medicines Agency's Cancer Medicines Pathfinder project, reflecting the high unmet medical need in pancreatic oncology.[3]
That approval was based on the Phase 3 RASolute 302 trial, which evaluated daraxonrasib against standard chemotherapy in 500 previously treated patients. The trial demonstrated a median overall survival of 13.2 months for the daraxonrasib group, compared to 6.7 months for the chemotherapy cohort.[3]
Progression-free survival in the RASolute 302 trial also doubled, reaching 7.2 months versus 3.6 months for standard care. The U.S. Food and Drug Administration had previously approved the drug under the brand name Rasonque on August 26, 2026, based on the same pivotal data.[3]
"For decades, physicians treating metastatic pancreatic cancer have had limited options beyond cytotoxic chemotherapy, underscoring the urgent need for new therapeutic approaches," said Dr. Thomas Seufferlein, a medical director at Ulm University Hospital. He called the European approval an important advance for patients.[3]
Managing the Safety Profile
While the efficacy data has generated optimism, researchers are closely monitoring the drug's safety profile. In the first-line combination trial, the adverse events were consistent with the known toxicities of both daraxonrasib and the chemotherapy agents gemcitabine and nab-paclitaxel.[6]
Common side effects of daraxonrasib include dermatologic toxicities, such as rash, and gastrointestinal issues like stomatitis, nausea, and diarrhea. When combined with chemotherapy, patients also experienced expected hematological side effects, including anemia and decreased neutrophil counts.[6]
Despite these toxicities, the combination regimen was generally well tolerated, with a mean dose intensity exceeding 80 percent for both the targeted therapy and the chemotherapy. Only a small percentage of patients had to permanently discontinue the treatment due to adverse events.[6]
The ability to maintain sufficient dose intensity is critical for sustaining the continuous suppression of RAS signaling. By keeping the cancer cells starved of their primary growth signal, the combination therapy leverages the additional antitumor contribution of the cytotoxic chemotherapy.[6]
Community oncologists are already adapting to the drug's unique management requirements. Following the U.S. approval in August 2026, cancer centers reported that administrative hurdles, rather than drug availability, were the primary barriers to initiating treatment promptly.[3]
Moving to First-Line Treatment
The durability of the responses seen in the Phase 1/2 data provides a compelling rationale for moving daraxonrasib to the front of the treatment sequence. The U.S. FDA recently granted Breakthrough Therapy Designation for the combination regimen in the first-line setting.[6]
Revolution Medicines is now enrolling patients in the global Phase 3 RASolute 303 trial. This three-arm study will evaluate daraxonrasib monotherapy and the combination of daraxonrasib plus chemotherapy, comparing both against a control arm of chemotherapy alone in treatment-naïve patients.[6]
Independent experts remain cautiously optimistic about the preliminary findings. Professor Shivan Sivakumar of the University of Birmingham noted that the 61-patient study lacked a randomized control group, meaning comparisons with historical chemotherapy results are not definitive.[2]
"What is particularly exciting is the potential to move beyond chemotherapy as the mainstay of treatment for pancreatic cancer," Sivakumar said. He emphasized that targeting a fundamental driver like RAS could usher in an era where molecular therapies meaningfully improve outcomes.[2]
"The ongoing international phase III RASolute 303 trial will be critical in determining whether this combination genuinely improves survival compared with standard chemotherapy," Sivakumar added. "If these findings are confirmed, this could represent one of the most significant advances in the first-line treatment of metastatic pancreatic cancer in recent years."[2]
Until those Phase 3 results mature, the early evidence of tumor eradication offers a tangible milestone. For a disease defined by its resistance to intervention, the ability to completely clear detectable tumors in a subset of patients marks a definitive shift in the therapeutic landscape.[4]
Sources
- [1]Bioengineer.org — Daraxonrasib Chemotherapy Combination Shows Promising Tumour Shrinkage in Metastatic Pancreatic Cancer Trial Read on Bioengineer.org →
- [2]Science Media Centre — expert reaction to abstract about Daraxonrasib plus GnP for metastatic pancreatic adenocarcinoma Read on Science Media Centre →
- [3]OncLive — Daraxonrasib Gains EC Approval in Previously Treated Metastatic Pancreatic Cancer Read on OncLive →
- [4]BBC — Massive hope for pancreatic cancer pill after trial saw tumours vanish Read on BBC →
- [5]EurekAlert! — Metastatic pancreatic cancer responds well to initial treatment with combination of daraxonrasib and chemotherapy Read on EurekAlert! →
- [6]Revolution Medicines — Revolution Medicines Presents Updated Phase 1/2 Data for RASONQUE® (daraxonrasib) Plus Chemotherapy in First-Line Metastatic Pancreatic Cancer at ENA 2026 Read on Revolution Medicines →
- [7]The BMJ — What is daraxonrasib? Read on The BMJ →
Charts, maps and images
Timeline
November 2026
Daraxonrasib Pill Eradicates Tumors in Early Pancreatic Cancer Trial
May 2026
Experimental Drug Daraxonrasib Doubles Survival Time in Metastatic Pancreatic Cancer Trial
AI
How the story developed
The clinical trajectory of daraxonrasib gained prominence on May 31, when Revolution Medicines presented Phase 3 clinical trial results at the ASCO 2026 meeting. The trial evaluated the drug in patients with previously treated metastatic pancreatic cancer, comparing its efficacy against standard chemotherapy.
Daraxonrasib is an oral pill designed to target the active "ON" state of the RAS protein. RAS mutations are known to drive approximately 90 percent of all pancreatic cancers.
In the Phase 3 trial, daraxonrasib doubled the median overall survival for patients to 13.2 months. Progression-free survival also doubled, reaching 7.2 months compared to the 3.6 months observed with standard chemotherapy.
The trial data showed that severe adverse events leading to the discontinuation of the treatment were significantly lower for daraxonrasib than for standard chemotherapy. Following these results, the Food and Drug Administration opened an Expanded Access Program for patients who had exhausted other treatment options.

